In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Motus Therapeutics Inc.

Division of Rhythm Pharmaceuticals Inc.

Latest From Motus Therapeutics Inc.

AbbVie And Allergan: Five Big Review Questions To Worry About

Mega-merger's top US drug candidates are seeking space in crowded fields. That means they have to get through the FDA fast, and priority review vouchers figure prominently in both improving and lowering the odds.

Drug Review M & A

Allergan's Big Deal: A Buyout, Not A Split, Appeases Wary Investors

Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.

Deals Business Strategies

Allergan Relying On 'Six Stars' And Other R&D Programs To Blunt Restasis Blow

Allergan will spend 2018 trying to shift investor focus from the loss of Restasis patent exclusivity in the second half of the year to the company's R&D pipeline, including the late-stage "six stars" highlighted in 2017 and mid-stage programs that are moving into the spotlight.

Business Strategies Research and Development Strategies

Allergan’s Namesake Acquisition Looks Well-Timed As Established Brands Falter

Allergan’s net product revenue in the third quarter fell slightly below analyst consensus, but revenue from the company’s 2015 purchase of Botox, Restasis and other products softened declines for established products Namenda and Asacol.

Companies Sales & Earnings
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
  • Alias(es)
  • Rhythm Health Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Rhythm Pharmaceuticals Inc.
  • Senior Management
  • Keith M Gottesdiener, MD, CEO
    Bart Henderson, Pres.
    Fred T Fiedorek, MD, CMO
    Lex Van der Ploeg, PhD, CSO
  • Contact Info
  • Motus Therapeutics Inc.
    Phone: (857) 264-4280
    855 Boylston St., 11th Fl.
    Boston, MA 02116
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register